Solubility Enhancement Program
Undisclosed
Key Facts
About Zylo Therapeutics
Zylö Therapeutics is a private, pre-revenue biotech company specializing in advanced topical drug delivery. Its core innovation is the Z-pods® platform—porous silica particles that encapsulate actives to provide sustained release over up to 24 hours, enhance penetration into the stratum corneum and hair follicles, and improve the solubility and stability of drugs. The company operates as a platform technology provider, seeking partnerships with cosmetic, OTC, and pharmaceutical companies to enhance their topical products, with initial applications targeting dermatology and skincare. While still in pre-clinical and development stages, Zylö has validated its technology through multiple studies and is actively pursuing commercial collaborations.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |